Shanghai Fudan Forward S&T Co., Ltd Stock

Equities

600624

CNE0000006S1

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-06-20 pm EDT 5-day change 1st Jan Change
3.19 CNY +0.31% Intraday chart for Shanghai Fudan Forward S&T Co., Ltd +1.59% -44.13%
Sales 2022 789M 109M Sales 2023 680M 93.61M Capitalization 3.88B 534M
Net income 2022 -3M -413K Net income 2023 5M 689K EV / Sales 2022 5.19 x
Net Debt 2022 207M 28.49M Net Debt 2023 211M 29.09M EV / Sales 2023 6.02 x
P/E ratio 2022
-1,078 x
P/E ratio 2023
634 x
Employees 1,363
Yield 2022 *
-
Yield 2023
-
Free-Float 65.6%
More Fundamentals * Assessed data
Dynamic Chart
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Fudan Forward S&T to Auction Office Property For At Least 31 Million Yuan MT
Fudan Forward S&T Chairman Retires MT
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Tranche Update on Shanghai Fudan Forward S&T Co., Ltd's Equity Buyback Plan announced on June 30, 2021. CI
Shanghai Fudan Forward S&T Co., Ltd's Equity Buyback announced on June 30, 2021, has expired with 5,365,068 shares, representing 0.78% for CNY 35.01 million. CI
Tranche Update on Shanghai Fudan Forward S&T Co., Ltd's Equity Buyback Plan announced on June 30, 2021. CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
More news
1 day+0.31%
1 week+1.59%
Current month-15.38%
1 month-20.25%
3 months-34.76%
6 months-44.23%
Current year-44.13%
More quotes
1 week
3.05
Extreme 3.05
3.41
1 month
2.97
Extreme 2.97
3.96
Current year
2.97
Extreme 2.97
5.95
1 year
2.97
Extreme 2.97
6.39
3 years
2.97
Extreme 2.97
8.07
5 years
2.97
Extreme 2.97
11.98
10 years
2.97
Extreme 2.97
17.96
More quotes
Managers TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal 40 20-12-07
Corporate Secretary 46 00-12-31
Members of the board TitleAgeSince
Director/Board Member 61 20-12-07
Corporate Officer/Principal 40 20-12-07
Director/Board Member 43 20-12-07
More insiders
Date Price Change Volume
24-06-21 3.19 +0.31% 13,606,470
24-06-20 3.18 +1.27% 16,894,870
24-06-19 3.14 -0.63% 5,024,087
24-06-18 3.16 +1.94% 6,164,533
24-06-17 3.1 -1.27% 5,765,045

End-of-day quote Shanghai S.E., June 20, 2024

More quotes
SHANGHAI FUDAN FORWARD S&T CO., LTD is a China-based company, principally engaged in the manufacture and distribution of pharmaceuticals. The Company's pharmaceuticals include digestive system drugs, nervous system drugs, antineoplastic drugs, circulatory drugs, immune function medications and others. The Company is also engaged in the provision of financial insurance software products. It distributes its products within domestic markets and to overseas markets.
More about the company
  1. Stock Market
  2. Equities
  3. 600624 Stock